Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

Hypertension Management Update


This CE activity was originally published in The Rx Consultant.  If you received credit for it previously, you cannot receive credit for it again.
 
Hypertension is the most common chronic condition seen by primary care providers, affecting 1 out of 3 adults in the United States. In many communities, fewer than half of people with hypertension have their blood pressure (BP) adequately controlled. Hypertension increases the risk of cardiovascular events, stroke, and kidney disease. Epidemiological studies have shown that these risks begin to rise as BP increases above 115/75 mm Hg – ie, starting at levels below those defined as hypertension or even pre-hypertension (Table 1). For every increase of 20/10 mm Hg, the risk of major cardiovascular events, including stroke, approximately doubles.

This issue of The Rx Consultant focuses on selected controversies and recent developments in the management of primary (essential) hypertension in adults. These include a new US guideline with new recommendations for when to start treatment; recommended options for initial antihypertensive drug therapy; hypertension management in black people; and an ongoing controversy about dietary sodium. It is important for all providers, including pharmacists, to be up to date on these developments; a team approach may help more patients achieve their BP goals. For background information about hypertension, see the July/August 2010 issue of The Rx Consultant.
Format
This CE activity is a monograph (PDF file).

Fee

$10.00

CE Hours

1.50

CE Units

0.150

Activity Type

  • Knowledge-based

Target Audience(s)

  • Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, and Registered Nurses

Accreditation(s)

This CE activity was developed by The Rx Consultant, a publication of Continuing Education Network, Inc.

CE activities for Pharmacists and Pharmacy Technicians:
This continuing education (CE) activity meets the requirements of all state boards of pharmacy for approved continuing education hours.  CE credit is automatically reported to CPE Monitor.
 
CE activities for Nurse Practitioners and Clinical Nurse Specialists: 
    This continuing education activity meets the requirements of:
        The American Nurses Credentialing Center (ANCC) for formally approved continuing education (CE) hours, and CE hours of pharmacotherapeutics.
        The American Academy of Nurse Practitioners Certification Program (AANPCP) for acceptable, accredited CE.
 
    This is a pharmacotherapeutics/pharmacology CE activity.
  • The ANCC requires all advanced practice nursing certificants (CNSs and NPs) to complete 25 CE hours of pharmacotherapeutics as a portion of the required 75 continuing education hours.
  • Pharmacology CE is recommended by the AANPCP and will be required for Certificants renewing certification starting January 2017.  
  • Most State Boards of Nursing require a minimum number of pharmacy contact hours to renew an advanced practice license.
 
 
Accreditation Council for Pharmacy Education
Continuing Education Network, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Requirements for CE Credit

To receive CE credit, the participant must read the monograph in its entirety, complete the online post-test and receive a score of 70% or greater, and complete the online evaluation.
 
Pharmacists and Pharmacy Technicians -
 
Be sure your profile has been updated with your NAPB e-profile # and birth date information BEFORE completing the online evaluation, or your credits cannot be reported to CPE Monitor.
 
Continuing pharmacy education credit is automatically reported to CPE Monitor once the post-test & evaluation are successfully completed.

 

 

 

Objectives

  • State the blood pressure goals recommended by the JNC8 guide- line, and discuss the controversy about them. Provide recommendations for initial antihypertensive therapy based on JNC8.
  • Discuss the role of ß-blockers in hypertension management. Describe potential differences between ACE inhibitors and ARBs, and between hydrochlorothiazide and chlorthalidone.
  • Discuss considerations for hypertension management in black people.
  • Describe the current controversy about optimal sodium intake.

Speaker(s)/Author(s)

Heather C. Ulrich, PharmD, BCPS, CDE


Brief Bio : Heather C. Ulrich, PharmD, BCPS, CDE, Clinical Pharmacist, Lebanon VA Medical Center, Lebanon, PA.
Disclosure : Dr. Ulrich reports no financial or personal relationship with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.

Pamela Mausner, MD


Brief Bio : Pamela Mausner, MD,Medical Writer/Editor and Healthcare Advocate.
Disclosure : Dr.Mausner reports no financial or personal relationship with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.

Tracy Farnen, PharmD


Brief Bio : PharmD, Associate Editor, The Rx Consultant.
Disclosure : Dr. Tracy Farnen reports no financial or personal relationship with any commercial interest producing, marketing, reselling, or distributing a product or service that appears in this issue.

Activity Number

0428-0000-14-012-H01-P

Release Date: Aug 25, 2014
Credit Expiration Date: Aug 25, 2017

CE Hours

1.50

Fee

$10.00
 

The CE Activity developed by The Rx Consultant